CY1113761T1 - Ενωσεις ισοξαζολιου ως αναστολεις πρωτεϊνων θερμικου σοκ - Google Patents

Ενωσεις ισοξαζολιου ως αναστολεις πρωτεϊνων θερμικου σοκ

Info

Publication number
CY1113761T1
CY1113761T1 CY20121101068T CY121101068T CY1113761T1 CY 1113761 T1 CY1113761 T1 CY 1113761T1 CY 20121101068 T CY20121101068 T CY 20121101068T CY 121101068 T CY121101068 T CY 121101068T CY 1113761 T1 CY1113761 T1 CY 1113761T1
Authority
CY
Cyprus
Prior art keywords
optionally substituted
group
alk2
alk1
formula
Prior art date
Application number
CY20121101068T
Other languages
Greek (el)
English (en)
Inventor
Martin James Drysdale
Brian William Dymock
Harry Finch
Paul Webb
Edward Mcdonald
Karen E James
Kwai M Cheung
Thomas P Mathews
Original Assignee
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303105A external-priority patent/GB0303105D0/en
Priority claimed from GBGB0306560.4A external-priority patent/GB0306560D0/en
Priority claimed from GB0313751A external-priority patent/GB0313751D0/en
Application filed by Vernalis (R&D) Limited filed Critical Vernalis (R&D) Limited
Publication of CY1113761T1 publication Critical patent/CY1113761T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
CY20121101068T 2003-02-11 2012-11-09 Ενωσεις ισοξαζολιου ως αναστολεις πρωτεϊνων θερμικου σοκ CY1113761T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0303105A GB0303105D0 (en) 2003-02-11 2003-02-11 Isoxazole compounds
GBGB0306560.4A GB0306560D0 (en) 2003-03-21 2003-03-21 Isoxazole compounds
GB0313751A GB0313751D0 (en) 2003-06-13 2003-06-13 Isoxazole compounds
EP04709273A EP1611112B1 (en) 2003-02-11 2004-02-09 Isoxazole compounds as inhibitors of heat shock proteins

Publications (1)

Publication Number Publication Date
CY1113761T1 true CY1113761T1 (el) 2016-07-27

Family

ID=32872455

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101068T CY1113761T1 (el) 2003-02-11 2012-11-09 Ενωσεις ισοξαζολιου ως αναστολεις πρωτεϊνων θερμικου σοκ

Country Status (18)

Country Link
US (6) US7705027B2 (https=)
EP (1) EP1611112B1 (https=)
JP (1) JP4921162B2 (https=)
KR (1) KR101166749B1 (https=)
CN (1) CN1771235B (https=)
AU (1) AU2004210779B2 (https=)
BR (1) BRPI0407403B1 (https=)
CA (1) CA2515726C (https=)
CY (1) CY1113761T1 (https=)
DK (1) DK1611112T3 (https=)
EA (1) EA009919B1 (https=)
ES (1) ES2393483T3 (https=)
MX (1) MXPA05008335A (https=)
NO (1) NO335001B1 (https=)
NZ (1) NZ541479A (https=)
PT (1) PT1611112E (https=)
SI (1) SI1611112T1 (https=)
WO (1) WO2004072051A1 (https=)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
JPWO2005063222A1 (ja) * 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
ATE538778T1 (de) 2004-05-28 2012-01-15 Unigen Inc 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'- dihydroxyphenyl)-propan als hochwirksamer tyrosinase-inhibitor
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CN1993318B (zh) 2004-06-23 2012-10-03 Synta医药公司 用于治疗癌症的双（硫代-酰肼酰胺）盐
JP4820758B2 (ja) 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
JPWO2006051808A1 (ja) 2004-11-09 2008-05-29 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
WO2006055760A1 (en) 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102005007304A1 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
NZ560712A (en) * 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
FR2882361A1 (fr) * 2005-02-22 2006-08-25 Aventis Pharma Sa Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation
JP4956737B2 (ja) * 2005-02-23 2012-06-20 国立大学法人名古屋大学 抗ポリグルタミン病剤
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
CN1834095B (zh) * 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
JP2008137894A (ja) * 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
KR101411167B1 (ko) 2005-04-13 2014-06-23 아스텍스 테라퓨틱스 리미티드 하이드록시벤즈아미드 유도체 및 ｈｓｐ90 억제제로서의이의 용도
WO2006113695A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
WO2006126751A1 (en) * 2005-05-25 2006-11-30 Korea Research Institute Of Bioscience And Biotechnology New diaryl-isoxazole derivatives, and pharmaceutical compositions containing the same for the prevention and the treatment of cancers
WO2007094819A2 (en) 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
GB0603880D0 (en) * 2006-02-27 2006-04-05 Novartis Ag Organic compounds
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
JP5249016B2 (ja) 2006-03-28 2013-07-31 日本化薬株式会社 タキサン類の高分子結合体
WO2007131034A1 (en) * 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
KR20090009241A (ko) 2006-05-18 2009-01-22 니폰 가야꾸 가부시끼가이샤 포도필로톡신류의 고분자 결합체
TWI440632B (zh) 2006-08-21 2014-06-11 Synta Pharmaceuticals Corp 用於治療增生性疾病的化合物
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ
AU2007294752A1 (en) * 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
ES2584840T3 (es) * 2006-10-03 2016-09-29 Nippon Kayaku Kabushiki Kaisha Compuesto de un derivado de resorcinol con un polímero
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008056596A1 (fr) 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Dérivé polymère d'un antagoniste métabolique d'acide nucléique
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
US7799954B2 (en) 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
CN101636162A (zh) * 2007-03-01 2010-01-27 诺瓦提斯公司 5-(2,4-二羟基-5-异丙基-苯基)-4-(4-吗啉-4-基甲基-苯基)-异唑-3-甲酸乙基酰胺的酸加成盐、水合物和多晶型物以及包含这些形式的制剂
EP2183237A1 (en) 2007-07-25 2010-05-12 F. Hoffmann-Roche AG Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
WO2009026658A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Ppar agonists
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US7932279B2 (en) 2007-10-12 2011-04-26 Arqule, Inc. Substituted tetrazole compounds and uses thereof
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
BRPI0817897A2 (pt) * 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
GB0722680D0 (en) * 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
WO2009116509A1 (ja) 2008-03-18 2009-09-24 日本化薬株式会社 生理活性物質の高分子結合体
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
LT5623B (lt) * 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
US20110124634A1 (en) * 2008-05-13 2011-05-26 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
CA2730265C (en) * 2008-07-21 2016-06-28 Unigen, Inc. Series of skin-whitening (lightening) compounds
CN105727297A (zh) * 2008-11-28 2016-07-06 诺华股份有限公司 包含hsp90抑制剂和mtor抑制剂的药物组合
MA32933B1 (fr) * 2008-11-28 2012-01-02 Novartis Ag Combinaison d'inhibiteurs de hspo90 et d'herceptine
WO2010121963A1 (en) 2009-04-21 2010-10-28 Nerviano Medical Sciences S.R.L. Resorcinol derivatives as hsp90 inhibitors
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
US20120283120A1 (en) 2009-09-29 2012-11-08 Takeda Pharmaceutical Company Limited Screening method
HUE026447T2 (en) 2009-10-16 2016-05-30 Novartis Ag Pharmacodynamic tumor response biomarkers
CN102753546A (zh) * 2010-02-17 2012-10-24 日东制药株式会社 新型5-元杂环衍生物及其制备方法
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2641605B1 (en) 2010-11-17 2018-03-07 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolism antagonist
AU2012231008B2 (en) 2011-03-24 2017-05-11 Unigen, Inc. Compounds and methods for preparation of diarylpropanes
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
CN102351655A (zh) * 2011-08-18 2012-02-15 杭州澳赛诺化工有限公司 一种4-异丙基间苯二酚的合成方法
KR101849142B1 (ko) 2011-09-11 2018-04-16 니폰 가야꾸 가부시끼가이샤 블록 공중합체의 제조방법
MX2014004559A (es) 2011-10-14 2014-08-01 Novartis Ag Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas.
CN103086994A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 异噁唑衍生物的盐
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2014074580A1 (en) 2012-11-07 2014-05-15 Novartis Ag Combination therapy
HRP20192020T1 (hr) * 2012-11-09 2020-02-07 Mmv Medicines For Malaria Venture Derivati heteroarila i njihova upotreba
WO2014074778A1 (en) 2012-11-09 2014-05-15 Jacobus Pharmaceutical Company, Inc. Aryl derivatives and uses thereof
WO2014141194A2 (en) * 2013-03-15 2014-09-18 Novartis Ag Biomarker
AU2014302458A1 (en) * 2013-06-26 2015-12-24 Proteostasis Therapeutics, Inc. Methods of modulating CFTR activity
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3157917B1 (en) * 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
EP3202766B1 (en) * 2014-10-01 2019-12-25 Daiichi Sankyo Company, Limited Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
CN104725329B (zh) * 2015-01-13 2017-01-18 陕西科技大学 一种具有抗肿瘤活性的异恶唑羧酸类化合物及其合成方法
JP6760946B2 (ja) * 2015-01-22 2020-09-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN107540624B (zh) * 2016-06-29 2020-06-16 广州市恒诺康医药科技有限公司 热休克蛋白抑制剂及其制备方法和应用
CN108191830B (zh) * 2016-06-30 2019-06-14 珠海赛隆药业股份有限公司（长沙）医药研发中心 一种富马酸沃诺拉赞中间体ⅳ及其制备方法
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN109641858B (zh) * 2016-07-21 2021-06-25 正大天晴药业集团股份有限公司 间苯二酚类衍生物的结晶、盐及其制备方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111217762B (zh) * 2018-11-23 2021-08-20 华中师范大学 多卤代5-(2-羟基苯基)异噁唑类化合物及其制备方法和应用
US20220362276A1 (en) * 2019-05-13 2022-11-17 The Trustees Of Princeton University Small Molecule Inhibitors of Viral Replication
CN110283080A (zh) * 2019-07-05 2019-09-27 山西大学 一种含氟的二苯甲酮衍生物及其制备方法和应用
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
WO2022075780A1 (ko) * 2020-10-07 2022-04-14 광주과학기술원 과민성 방광의 예방 또는 치료용 약학적 조성물
CN115160250B (zh) * 2021-04-02 2024-06-04 沈阳药科大学 4,6-联苯二酚类衍生物及其用途
US11324737B1 (en) * 2021-05-25 2022-05-10 Louis Habash Modulating expression level of a gene encoding a heat shock protein by treating a human subject with a nitroxide
US11729925B2 (en) 2021-06-15 2023-08-15 Erico International Corporation Mounting bracket with angled mounting openings for electrical boxes
CN114751870B (zh) * 2022-02-28 2023-10-20 贵州医科大学 一种2-(异噁唑-5-基)苯基-3,4-二羟基苯甲酸酯及其衍生物及合成方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0418667B1 (de) * 1989-09-22 1995-08-16 BASF Aktiengesellschaft Carbonsäureamide
WO1992019604A1 (en) * 1991-05-01 1992-11-12 Taiho Pharmaceutical Co., Ltd. Novel isoxazole derivative and salt thereof
WO1994024095A1 (en) * 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
CZ298022B6 (cs) * 1996-10-15 2007-05-30 G. D. Searle & Co. Použití inhibitoru cyklooxygenázy-2 pro výrobu léciva pro lécení a prevenci neoplazie
CA2276034A1 (en) * 1996-12-23 1998-07-02 Mimi Lifen Quan Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
EP1102755B1 (en) 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
ATE246197T1 (de) * 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
IL143569A0 (en) * 1998-12-24 2002-04-21 Metabasis Therapeutics Inc A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
CA2396713A1 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
JP2002363079A (ja) * 2001-05-31 2002-12-18 National Cancer Center-Japan モフェゾラクを有効成分とする、消化管ポリープおよび／または消化管がんの予防または治療のための薬剤
EP1456180B1 (en) * 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
EA009919B1 (ru) * 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use

Also Published As

Publication number Publication date
EA009919B1 (ru) 2008-04-28
NO20054195L (no) 2005-11-09
BRPI0407403A (pt) 2006-10-03
US8450310B2 (en) 2013-05-28
NZ541479A (en) 2008-11-28
CN1771235A (zh) 2006-05-10
EP1611112B1 (en) 2012-08-22
KR20050103925A (ko) 2005-11-01
US20170326152A1 (en) 2017-11-16
BRPI0407403B1 (pt) 2022-07-19
EP1611112A1 (en) 2006-01-04
CA2515726A1 (en) 2004-08-26
US20190358241A1 (en) 2019-11-28
JP4921162B2 (ja) 2012-04-25
US7705027B2 (en) 2010-04-27
AU2004210779A1 (en) 2004-08-26
CA2515726C (en) 2012-07-10
MXPA05008335A (es) 2006-05-04
US8507480B2 (en) 2013-08-13
HK1091831A1 (zh) 2007-01-26
US9718793B2 (en) 2017-08-01
US20130289026A1 (en) 2013-10-31
AU2004210779B2 (en) 2010-06-10
US11234987B2 (en) 2022-02-01
NO335001B1 (no) 2014-08-18
DK1611112T3 (da) 2012-11-19
WO2004072051A1 (en) 2004-08-26
PT1611112E (pt) 2012-11-02
EA200501272A1 (ru) 2006-02-24
US10413550B2 (en) 2019-09-17
SI1611112T1 (sl) 2012-12-31
NO20054195D0 (no) 2005-09-09
US20120252797A1 (en) 2012-10-04
JP2006517572A (ja) 2006-07-27
US20100179138A1 (en) 2010-07-15
KR101166749B1 (ko) 2012-07-27
US20060241106A1 (en) 2006-10-26
ES2393483T3 (es) 2012-12-21
CN1771235B (zh) 2010-04-28

Similar Documents

Publication Publication Date Title
CY1113761T1 (el) Ενωσεις ισοξαζολιου ως αναστολεις πρωτεϊνων θερμικου σοκ
NO20061416L (no) Pyrimidotiofenforbindelser
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
CY1110434T1 (el) Παραγωγα ν-πυρρολιδιν-3-υλ-αμιδιου ως αναστολεις επαναπροσληψεως σεροτονινης και νοραδρεναλινης
DE60304059D1 (de) 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs
CY1121599T1 (el) Νεο παραγωγο αμινης ή αλας αυτου ως παρεμποδιστες tnf αλφα
TNSN06419A1 (en) N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
JP2016536363A5 (https=)
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
CY1114001T1 (el) Συντηγμενες ετεροκυκλικες ενωσεις χρησιμες ως ρυθμιστες κινασης
CY1105250T1 (el) Μεθοδος θepαπευτικης αγωγης καταστασεων σχετιζομενων με κιναση ρ38 και ενωσεις πυρρολοτριαζινης χρησιμες ως αναστολεις της κινασης
IS6309A (is) Kínasólínafleiður
PE20080611A1 (es) Compuestos de azabenzofuranil y metodos de uso
CY1110960T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ 4-(2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ)ΦΑΙΝΟΛΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΤΟΥ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΥΠΟΔΟΧΕΑ
JP2016536364A5 (https=)
CY1111083T1 (el) Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38
MY143203A (en) Novel compounds having inhibitory activity against sodium-dependent transporter
CY1107978T1 (el) Νeα παρaγωγα πυριδαζiν -3 (2h) - oνης
PE20110294A1 (es) Compuestos heterociclicos como inhibidores de enzimas de senal especifica
MXPA05008878A (es) Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
CY1112533T1 (el) Μεθοδοι και ενωσεις για την παρασκευη αναλογων cc-1065
CY1117287T1 (el) Πυρρολιδινονη ως αναστολεις metap-2
MX2008011559A (es) Derivados de pirrolopirimidina utilizados como inhibidores de hsp90.
MX2010001170A (es) Derivados de imidazolona, metodo de preparacion de los mismos y uso biologico de los mismos.